Skip Navigation



Annals of Oncology Advance Access published online on June 26, 2006
Annals of Oncology, doi:10.1093/annonc/mdl105
This Article
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 4 iss...
Right arrow All Versions of this Article:
17/12/1733    most recent
mdl105v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Susini, C.
Right arrow Articles by Buscail, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Susini, C.
Right arrow Articles by Buscail, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received July 20, 2005
Revised March 31, 2006
Accepted April 4, 2006

review

Rationale for the use of somatostatin analogs as antitumor agents

C. Susini 1 * and L. Buscail 1

1 INSERM U151, Institut Louis Bugnard, Toulouse, France

* To whom correspondence should be addressed.
C. Susini, E-mail: Christiane.Susini{at}toulouse.inserm.fr


  Abstract

Background: There is a need for novel antitumor agents that demonstrate efficacy in currently refractory tumors without adding to the toxicity of therapy. The somatostatin analogs, which have demonstrated antineoplastic activities in experimental tumor models, and good tolerability and safety profiles are attractive candidates.

Materials and Methods: Data from preclinical studies provide evidence for direct and indirect mechanisms by which somatostatin analogs exert antitumor effects.

Results: Direct antitumor activities, mediated through somatostatin receptors (sst1-sst5) expressed in tumor cells, include blockade of autocrine/paracrine growth-promoting hormone and growth factor production, inhibition of growth factor-mediated mitogenic signals and induction of apoptosis. Indirect antitumor effects include inhibition of growth-promoting hormone and growth factor secretion, and antiangiogenic actions. Many human tumors express more than one somatostatin receptor subtype, with sst2 being predominant. Somatostatin analogs such as octreotide and lanreotide, which present a high affinity for sst2, are in current clinical use to alleviate symptoms in patients with endocrine tumors, and radiolabeled somatostatin analogs have been developed for diagnosis and radiotherapy.

Conclusions: While the rationale exists for the use of somatostatin analogs as antitumor agents, studies are ongoing to identify analogs with activity across the range of receptor subtypes to maximize the potential of such treatment.

Keywords: angiogenesis; apoptosis; antitumor; receptor; refractory tumor; somatostatin analog.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 EndocrinologyHome page
F. Barbieri, A. Pattarozzi, M. Gatti, C. Porcile, A. Bajetto, A. Ferrari, M. D. Culler, and T. Florio
Somatostatin Receptors 1, 2, and 5 Cooperate in the Somatostatin Inhibition of C6 Glioma Cell Proliferation in Vitro via a Phosphotyrosine Phosphatase-{eta}-Dependent Inhibition of Extracellularly Regulated Kinase-1/2
Endocrinology, September 1, 2008; 149(9): 4736 - 4746.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Torrisani, N. Hanoun, H. Laurell, F. Lopez, J.-J. Maoret, A. Souque, C. Susini, P. Cordelier, and L. Buscail
Identification of an Upstream Promoter of the Human Somatostatin Receptor, hSSTR2, Which Is Controlled by Epigenetic Modifications
Endocrinology, June 1, 2008; 149(6): 3137 - 3147.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. R. Halfdanarson, K. G. Rabe, J. Rubin, and G. M. Petersen
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
Ann. Onc., May 30, 2008; (2008) mdn351v1.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Moreno, A. Akcakanat, M. F Munsell, A. Soni, J. C Yao, and F. Meric-Bernstam
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
Endocr. Relat. Cancer, March 1, 2008; 15(1): 257 - 266.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Asnacios, F. Courbon, P. Rochaix, E. Bauvin, V. Cances-Lauwers, C. Susini, S. Schulz, A. Boneu, R. Guimbaud, and L. Buscail
Indium-111-Pentetreotide Scintigraphy and Somatostatin Receptor Subtype 2 Expression: New Prognostic Factors for Malignant Well-Differentiated Endocrine Tumors
J. Clin. Oncol., February 20, 2008; 26(6): 963 - 970.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
L. A. Nolan, H. A. Schmid, and A. Levy
Octreotide and the Novel Multireceptor Ligand Somatostatin Receptor Agonist Pasireotide (SOM230) Block the Adrenalectomy-Induced Increase in Mitotic Activity in Male Rat Anterior Pituitary
Endocrinology, June 1, 2007; 148(6): 2821 - 2827.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.